



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO). F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/069,386 09/12/2002		Moulay A. Alaoui-Jamali	SWA-001US)	3268	
32254	7590	01/12/2006		EXAMINER	
KEOWN	& ASSOC	CIATES	WHITEMAN, BRIAN A		
500 WEST	CUMMIN	GS PARK			<u> </u>
SUITE 1200				ART UNIT	PAPER NUMBER
WOBURN	, MA 018	801	1635		

DATE MAILED: 01/12/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/069,386	ALAOUI-JAMALI ET AL.		
Examiner	Art Unit		
Brian Whiteman	1635		

	Brian Whiteman	1635	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress
THE REPLY FILED 12/27/05 FAILS TO PLACE THIS APPLICA	ATION IN CONDITION FOR ALLO	WANCE.	
 The reply was filed after a final rejection, but prior to or o this application, applicant must timely file one of the followances the application in condition for allowance; (2) a Notation (3) a Request for Continued Examination (RCE) in comp following time periods: 	owing replies: (1) an amendment, a otice of Appeal (with appeal fee) in liance with 37 CFR 1.114. The rep	ffidavit, or other evidence with 37 (ence, which CFR 41.31; or
 a)	isory Action, or (2) the date set forth in than SIX MONTHS from the mailing date on the CHECK BOX (b) WHEN THE Figure 1.	f the final rejection. IRST REPLY WAS FILE	D WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension final Office action; or (2)	on fee under 37 as set forth in (b)
 The Notice of Appeal was filed on A brief in com of filing the Notice of Appeal (37 CFR 41.37(a)), or any e Since a Notice of Appeal has been filed, any reply must I AMENDMENTS 	extension thereof (37 CFR 41.37(e)), to avoid dismissal (of the appeal.
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below	nsideration and/or search (see NC		because
 (c) \overline{\text{They are not deemed to place the application in be appeal; and/or} (d) \overline{\text{They present additional claims without canceling a} 			; the issues for
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.14. The amendments are not in compliance with 37 CFR 1.15. Applicant's reply has overcome the following rejection(s. Newly proposed or amended claim(s) would be a	121. See attached Notice of Non-C):		
the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proposed. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 1,3 and 10. Claim(s) objected to: 2 and 4. Claim(s) rejected: 6. Claim(s) withdrawn from consideration: 11.			
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e).	-	* *	
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessarily	overcome <u>all</u> rejections under appe	eal and/or appellant fa	ails to provide a
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after	entry is below or atta	ched.
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application	in condition for allowa	ance because:
 12. ☐ Note the attached Information Disclosure Statement(s). 13. ☒ Other: See Continuation Sheet. 	(PTO/SB/08 or PTO-1449) Paper	No(s)	
		Prin Late	ma

-Continuation Sheet (PTOL-303)

Application No.

Continuation of 3. NOTE: The proposed amendment to the claim would require further consideration under 112 first paragraph enablement, new matter, and second paragraph.

Continuation of 11. does NOT place the application in condition for allowance because: the argument for claim 6 is based on a proposed amendment that was not entered.

Continuation of 13. Other: The objection to the specification for introducing new matter into the specification and the 112 first paragraph new matter rejection for claims 2 and 4 are withdrawn in view of the Declaration by Dr. Alaoui-Jamali. The Declaration displays that SEQ ID NO: 1 and 2 were isolated from human cells as shown on page 7, lines 2-5. and the BLASTN search on page 6 only identified human ESTs. The Declaration further displays that the inventors were in possession of the human sequence before the filing date of the application.

In view of the Declaration, claims 2 and 4 are objected to because they do not further limit the claim from which they depend from. The nucleic acid encoding the amino acid sequence as set forth in SEQ ID NO: 2 as recited in claim 1 is from a human. The amino acid sequence as set forth in SEQ ID NO: 2 is from a human. Thus, Claims 2 and 4 are redundant